The Only Accurate Point-of-Care Liver Fat Measurement Device Transformative Liver Disease Diagnostics Livivos
  • Our Goal

    Livivos's goal is to make liver disease diagnosis broadly available by providing accurate, rapid, and accessible Point-of-Care testing.
  • Diagnostics

    There is a fast-growing demand for accurate and affordable diagnosis of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
  • LiverScope®

    The LiverScope® offers the accuracy of MRI at the cost and simpler to use than ultrasound devices. LiverScope is not FDA cleared.

“The diagnosis of NASH can be difficult, as most patients in early stages of the disease have no symptoms. The identification of patients is currently not possible by a typical physical examination.”

The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma. 

“Signs of the disease are asymptomatic, so a person often is not diagnosed with NASH until it advances to a late stage, when cirrhosis begins to ravage the body”.

CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans. 

Liver Disease Prevalence

Fatty liver disease has reached epidemic proportions worldwide, affecting over 20% of the population and increasing at a remarkable pace.

Nonalcoholic steatohepatitis (NASH), the progressive form of Non-alcoholic fatty liver disease (NAFLD), can lead to cirrhosis, cardiovascular problems, hepatocellular carcinoma, and even death. Liver disease is reversible if detected early on. If diagnosed in advanced stages, it often cannot be cured.

There is a critical need for reliable and easily accessed liver disease diagnosis. Yet, no accurate Point-of-Care diagnosis exists.

Improved Diagnostics

LiverScope® provides instant accurate results, without the need for image interpretation or histological examination – overcoming critical deficiencies of standard diagnostic modalities.

Livivos’s technology transforms liver disease diagnostics, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support accurate evaluation of the response to treatments.

Other liver disease diagnostic modalities are invasive, expensive or inaccurate:

Liver Disease Prevalence

There are 64 million individuals with NAFLD in the United States and 52 million total in Germany, France, Italy, and the UK. The global prevalence of NAFLD is estimated to be 24%. 1.75 million individuals die of liver disease each year. In addition, a high prevalence of obesity has been reported in South America, Asia, and the Middle East. The number of affected people and the economic burden are expected to increase.

Source: Hepatology, Vol. 64-5:1577, 2016.

Economic Burden

Current NAFLD trends indicate that the disease will soon be the leading cause of liver transplant. There is a rapid increase in the number of drugs targeting this disease that are undergoing clinical trial. The critical prevalence of fatty liver disease comes with an associated annual direct medical cost of over $100 billion, in the United States alone, with a significantly higher burden when societal costs are included.

Source: Gut 69(3):564, 2020.

Preventive Medicine

NAFLD & NASH diagnosis is often delayed by the burdens of the diagnosis methods: biopsy – invasive and costly – and MRI – costly and of limited availability. Accurate and non-invasive diagnostic is critical to reverse the disease trend. Livivos’s method provides high accuracy and repeatability at lower cost than traditional modalities. LiverScope® offers the possibility to reverse the growth trend of liver disease.

Source: Gut 69(3):564, 2020.

Clinical markets benefiting from effective liver disease diagnostics


Preventive medicine, clinical triage for the millions of patients with suspected NAFLD, and accurate over-time treatment monitoring.


Supporting regulatory clinical trials. There is a rapid increase in the number of liver disease drugs undergoing FDA evaluation. Livivos’s technology provides biomarkers to quantify the evolution of steatosis.


Monitoring of drug effectiveness after drug approval – especially for NASH drugs with anti-steatotic mechanisms of action – as they enter the clinical market.